JP2020517967A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020517967A5 JP2020517967A5 JP2019558662A JP2019558662A JP2020517967A5 JP 2020517967 A5 JP2020517967 A5 JP 2020517967A5 JP 2019558662 A JP2019558662 A JP 2019558662A JP 2019558662 A JP2019558662 A JP 2019558662A JP 2020517967 A5 JP2020517967 A5 JP 2020517967A5
- Authority
- JP
- Japan
- Prior art keywords
- iaip
- subject
- sample
- kit according
- kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 250
- 239000003446 ligand Substances 0.000 claims description 76
- 239000003795 chemical substances by application Substances 0.000 claims description 33
- 238000001514 detection method Methods 0.000 claims description 33
- 239000011230 binding agent Substances 0.000 claims description 31
- 101001082142 Homo sapiens Pentraxin-related protein PTX3 Proteins 0.000 claims description 16
- 102100027351 Pentraxin-related protein PTX3 Human genes 0.000 claims description 16
- 102000004190 Enzymes Human genes 0.000 claims description 12
- 108090000790 Enzymes Proteins 0.000 claims description 12
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 11
- 229920000669 heparin Polymers 0.000 claims description 11
- 229960002897 heparin Drugs 0.000 claims description 11
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 10
- 230000000295 complement effect Effects 0.000 claims description 10
- 239000002245 particle Substances 0.000 claims description 10
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 9
- 102100022641 Coagulation factor IX Human genes 0.000 claims description 9
- 108010076282 Factor IX Proteins 0.000 claims description 9
- 108010033040 Histones Proteins 0.000 claims description 9
- 229960004222 factor ix Drugs 0.000 claims description 9
- 229920002674 hyaluronan Polymers 0.000 claims description 9
- 229960003160 hyaluronic acid Drugs 0.000 claims description 9
- 108010000196 Factor XIIIa Proteins 0.000 claims description 8
- 102100037362 Fibronectin Human genes 0.000 claims description 8
- 108010067306 Fibronectins Proteins 0.000 claims description 8
- 108010085895 Laminin Proteins 0.000 claims description 8
- 108700039882 Protein Glutamine gamma Glutamyltransferase 2 Proteins 0.000 claims description 8
- 102100038095 Protein-glutamine gamma-glutamyltransferase 2 Human genes 0.000 claims description 8
- 102000007000 Tenascin Human genes 0.000 claims description 8
- 108010008125 Tenascin Proteins 0.000 claims description 8
- 102100035140 Vitronectin Human genes 0.000 claims description 8
- 108010031318 Vitronectin Proteins 0.000 claims description 8
- 239000012530 fluid Substances 0.000 claims description 8
- 239000002105 nanoparticle Substances 0.000 claims description 8
- 239000000758 substrate Substances 0.000 claims description 7
- 210000001519 tissue Anatomy 0.000 claims description 7
- 102000007547 Laminin Human genes 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 238000000018 DNA microarray Methods 0.000 claims description 5
- 239000011324 bead Substances 0.000 claims description 5
- 239000011616 biotin Substances 0.000 claims description 5
- 229960002685 biotin Drugs 0.000 claims description 5
- 235000020958 biotin Nutrition 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 239000007850 fluorescent dye Substances 0.000 claims description 5
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 5
- 239000012528 membrane Substances 0.000 claims description 5
- 239000011347 resin Substances 0.000 claims description 5
- 229920005989 resin Polymers 0.000 claims description 5
- 206010036790 Productive cough Diseases 0.000 claims description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 4
- 108010093564 inter-alpha-inhibitor Proteins 0.000 claims description 4
- 210000002381 plasma Anatomy 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 210000003802 sputum Anatomy 0.000 claims description 4
- 208000024794 sputum Diseases 0.000 claims description 4
- 210000001179 synovial fluid Anatomy 0.000 claims description 4
- 206010003445 Ascites Diseases 0.000 claims description 3
- 210000004381 amniotic fluid Anatomy 0.000 claims description 3
- 210000000941 bile Anatomy 0.000 claims description 3
- 210000003722 extracellular fluid Anatomy 0.000 claims description 3
- 210000001733 follicular fluid Anatomy 0.000 claims description 3
- 210000004251 human milk Anatomy 0.000 claims description 3
- 235000020256 human milk Nutrition 0.000 claims description 3
- 210000002751 lymph Anatomy 0.000 claims description 3
- 210000002700 urine Anatomy 0.000 claims description 3
- 239000002981 blocking agent Substances 0.000 claims description 2
- 101800001691 Inter-alpha-trypsin inhibitor light chain Proteins 0.000 claims 4
- 102100032859 Protein AMBP Human genes 0.000 claims 4
- 239000010931 gold Substances 0.000 claims 3
- 229910052737 gold Inorganic materials 0.000 claims 3
- 150000001768 cations Chemical class 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 108090001008 Avidin Proteins 0.000 claims 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims 1
- 108010090804 Streptavidin Proteins 0.000 claims 1
- 239000004816 latex Substances 0.000 claims 1
- 229920000126 latex Polymers 0.000 claims 1
- 239000006249 magnetic particle Substances 0.000 claims 1
- 108010037710 pre-alpha-trypsin inhibitor Proteins 0.000 claims 1
- 239000011534 wash buffer Substances 0.000 claims 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 61
- 241000588747 Klebsiella pneumoniae Species 0.000 description 38
- 208000015181 infectious disease Diseases 0.000 description 38
- 208000027866 inflammatory disease Diseases 0.000 description 34
- 239000000523 sample Substances 0.000 description 25
- 241000607479 Yersinia pestis Species 0.000 description 14
- 206010028980 Neoplasm Diseases 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 208000035473 Communicable disease Diseases 0.000 description 10
- 206010061218 Inflammation Diseases 0.000 description 8
- 241000588748 Klebsiella Species 0.000 description 8
- 241000606860 Pasteurella Species 0.000 description 8
- 241000589516 Pseudomonas Species 0.000 description 8
- 206010040047 Sepsis Diseases 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 8
- 230000001154 acute effect Effects 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- -1 container Substances 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 208000014674 injury Diseases 0.000 description 8
- 208000028867 ischemia Diseases 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 238000001356 surgical procedure Methods 0.000 description 8
- 229940124597 therapeutic agent Drugs 0.000 description 8
- 241000589248 Legionella Species 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 241000605909 Fusobacterium Species 0.000 description 5
- 241000607142 Salmonella Species 0.000 description 5
- 208000009304 Acute Kidney Injury Diseases 0.000 description 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 4
- 206010003210 Arteriosclerosis Diseases 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 4
- 241000606125 Bacteroides Species 0.000 description 4
- 241000606124 Bacteroides fragilis Species 0.000 description 4
- 241000589562 Brucella Species 0.000 description 4
- 241000589876 Campylobacter Species 0.000 description 4
- 241000589875 Campylobacter jejuni Species 0.000 description 4
- 206010065929 Cardiovascular insufficiency Diseases 0.000 description 4
- 206010048964 Carotid artery occlusion Diseases 0.000 description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 4
- 208000034656 Contusions Diseases 0.000 description 4
- 241000588914 Enterobacter Species 0.000 description 4
- 241000589601 Francisella Species 0.000 description 4
- 241000589602 Francisella tularensis Species 0.000 description 4
- 241000605986 Fusobacterium nucleatum Species 0.000 description 4
- 241000606790 Haemophilus Species 0.000 description 4
- 241000606768 Haemophilus influenzae Species 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 4
- 206010067125 Liver injury Diseases 0.000 description 4
- 201000009906 Meningitis Diseases 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 206010033645 Pancreatitis Diseases 0.000 description 4
- 206010033647 Pancreatitis acute Diseases 0.000 description 4
- 208000018262 Peripheral vascular disease Diseases 0.000 description 4
- 206010035664 Pneumonia Diseases 0.000 description 4
- 208000005107 Premature Birth Diseases 0.000 description 4
- 206010036590 Premature baby Diseases 0.000 description 4
- 241000588769 Proteus <enterobacteria> Species 0.000 description 4
- 241000588770 Proteus mirabilis Species 0.000 description 4
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 4
- 206010037448 Pulmonary valve incompetence Diseases 0.000 description 4
- 208000033626 Renal failure acute Diseases 0.000 description 4
- 206010040070 Septic Shock Diseases 0.000 description 4
- 241001478880 Streptobacillus moniliformis Species 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 4
- 206010064390 Tumour invasion Diseases 0.000 description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 4
- 201000011040 acute kidney failure Diseases 0.000 description 4
- 206010069351 acute lung injury Diseases 0.000 description 4
- 201000003229 acute pancreatitis Diseases 0.000 description 4
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 229940127219 anticoagulant drug Drugs 0.000 description 4
- 229940121375 antifungal agent Drugs 0.000 description 4
- 239000003096 antiparasitic agent Substances 0.000 description 4
- 229940124630 bronchodilator Drugs 0.000 description 4
- 230000009400 cancer invasion Effects 0.000 description 4
- 239000004074 complement inhibitor Substances 0.000 description 4
- 230000009519 contusion Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 229940118764 francisella tularensis Drugs 0.000 description 4
- 229940047650 haemophilus influenzae Drugs 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 231100000753 hepatic injury Toxicity 0.000 description 4
- 239000005555 hypertensive agent Substances 0.000 description 4
- 230000001146 hypoxic effect Effects 0.000 description 4
- 230000000302 ischemic effect Effects 0.000 description 4
- 208000017169 kidney disease Diseases 0.000 description 4
- 208000030175 lameness Diseases 0.000 description 4
- 208000018773 low birth weight Diseases 0.000 description 4
- 231100000533 low birth weight Toxicity 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 201000006417 multiple sclerosis Diseases 0.000 description 4
- 208000010125 myocardial infarction Diseases 0.000 description 4
- 208000037931 necrotizing enteritis Diseases 0.000 description 4
- 208000033808 peripheral neuropathy Diseases 0.000 description 4
- 201000010298 pulmonary valve insufficiency Diseases 0.000 description 4
- 230000029058 respiratory gaseous exchange Effects 0.000 description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 description 4
- 206010039083 rhinitis Diseases 0.000 description 4
- 230000036303 septic shock Effects 0.000 description 4
- 230000008733 trauma Effects 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- 210000003954 umbilical cord Anatomy 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 208000007764 Legionnaires' Disease Diseases 0.000 description 3
- 241000588655 Moraxella catarrhalis Species 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 description 3
- 239000003429 antifungal agent Substances 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 229940125687 antiparasitic agent Drugs 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 239000002955 immunomodulating agent Substances 0.000 description 3
- 229940121354 immunomodulator Drugs 0.000 description 3
- 239000000932 sedative agent Substances 0.000 description 3
- 229940125723 sedative agent Drugs 0.000 description 3
- 229940124073 Complement inhibitor Drugs 0.000 description 2
- 241000589242 Legionella pneumophila Species 0.000 description 2
- 206010061876 Obstruction Diseases 0.000 description 2
- 241001478878 Streptobacillus Species 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000000168 bronchodilator agent Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000002584 immunomodulator Effects 0.000 description 2
- 229940115932 legionella pneumophila Drugs 0.000 description 2
- 239000013074 reference sample Substances 0.000 description 2
- 241001534216 Klebsiella granulomatis Species 0.000 description 1
- 241001192930 Pustula Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023023295A JP2023085249A (ja) | 2017-04-25 | 2023-02-17 | インターα阻害剤タンパク質を定量化する方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762490003P | 2017-04-25 | 2017-04-25 | |
| US62/490,003 | 2017-04-25 | ||
| US201862614333P | 2018-01-05 | 2018-01-05 | |
| US62/614,333 | 2018-01-05 | ||
| PCT/US2018/029436 WO2018200722A1 (en) | 2017-04-25 | 2018-04-25 | Methods for quantifying inter-alpha inhibitor proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023023295A Division JP2023085249A (ja) | 2017-04-25 | 2023-02-17 | インターα阻害剤タンパク質を定量化する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020517967A JP2020517967A (ja) | 2020-06-18 |
| JP2020517967A5 true JP2020517967A5 (https=) | 2021-06-10 |
| JP7293128B2 JP7293128B2 (ja) | 2023-06-19 |
Family
ID=63920445
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019558662A Active JP7293128B2 (ja) | 2017-04-25 | 2018-04-25 | インターα阻害剤タンパク質を定量化する方法 |
| JP2023023295A Withdrawn JP2023085249A (ja) | 2017-04-25 | 2023-02-17 | インターα阻害剤タンパク質を定量化する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023023295A Withdrawn JP2023085249A (ja) | 2017-04-25 | 2023-02-17 | インターα阻害剤タンパク質を定量化する方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20200057077A1 (https=) |
| EP (1) | EP3615937B1 (https=) |
| JP (2) | JP7293128B2 (https=) |
| KR (1) | KR102587810B1 (https=) |
| CN (1) | CN110691973B (https=) |
| AU (1) | AU2018258466B2 (https=) |
| BR (1) | BR112019022358A2 (https=) |
| CA (1) | CA3061164A1 (https=) |
| IL (1) | IL270069B1 (https=) |
| WO (1) | WO2018200722A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018053029A1 (en) | 2016-09-13 | 2018-03-22 | Prothera Biologics, Inc. | Methods for treating pulmonary disease using inter-alpha inhibitor proteins |
| BR112019022358A2 (pt) | 2017-04-25 | 2020-05-19 | Prothera Biologics, Inc. | métodos para quantificar proteínas inibidoras inter-alfa |
| US20210393750A1 (en) * | 2018-10-24 | 2021-12-23 | Prothera Biologics, Inc. | Inter-alpha inhibitor proteins and methods of use thereof |
| US20230416342A1 (en) | 2020-11-16 | 2023-12-28 | Prothera Biologics, Inc. | Methods for purifying inter-alpha inhibitor proteins |
| US20230055086A1 (en) * | 2021-08-19 | 2023-02-23 | Prothera Biologics, Inc. | Inter-alpha inhibitor proteins |
| CN114088949B (zh) * | 2021-11-11 | 2024-09-27 | 王南 | 乌司他丁前体用于检测炎症的应用 |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3832253A (en) | 1973-03-21 | 1974-08-27 | Baxter Laboratories Inc | Method of making an inflatable balloon catheter |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4667014A (en) | 1983-03-07 | 1987-05-19 | Syntex (U.S.A.) Inc. | Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists |
| US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
| CA1200416A (en) | 1983-05-13 | 1986-02-11 | Societe Des Produits Nestle S.A. | Food process |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| US4839298A (en) | 1986-02-14 | 1989-06-13 | Akzo N.V. | Virus inactivating diluents used in immunoassays |
| EP0367090B1 (en) | 1988-11-01 | 1994-01-12 | Schwarz Pharma Ag | Lyophilized MDM composition and method of making it |
| GB8928501D0 (en) | 1989-12-18 | 1990-02-21 | Unilever Plc | Reagents |
| JPH04167172A (ja) | 1990-10-31 | 1992-06-15 | Nec Corp | ベクトルプロセッサ |
| US5166133A (en) | 1991-04-17 | 1992-11-24 | Cetus Corporation | Method for inhibing adhesion of white blood cells to endothelial cells |
| FR2706466B1 (fr) | 1993-06-14 | 1995-08-25 | Aetsrn | Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré. |
| FR2711371B1 (fr) | 1993-10-18 | 1995-12-29 | Aetsrn | Procédé de préparation d'un concentré d'inter-alpha-trypsine inhibiteur à usage thérapeutique et concentré obtenu. |
| US6313091B1 (en) | 1995-07-20 | 2001-11-06 | New York University | Pharmaceutical compositions containing TSG-6 for treating inflammatory diseases and cancer-related pathologies and method |
| JP4217717B2 (ja) * | 1996-07-16 | 2009-02-04 | 生化学工業株式会社 | 血清由来ヒアルロナン結合性タンパク質−ヒアルロン酸結合体の測定法および測定キット |
| AU5134799A (en) | 1998-07-30 | 2000-02-21 | Human Genome Sciences, Inc. | 98 human secreted proteins |
| US6673908B1 (en) | 1999-02-22 | 2004-01-06 | Nuvelo, Inc. | Tumor necrosis factor receptor 2 |
| US6489128B1 (en) | 2000-01-24 | 2002-12-03 | Rhode Island Hospital, A Lifespan Partner | Methods for detecting cancer of the central nervous system |
| US6660482B1 (en) | 2000-02-28 | 2003-12-09 | Rhode Island Hospital | Inter-alpha-trypsin inhibitor as a marker for sepsis |
| EP1326893A2 (de) | 2000-10-13 | 2003-07-16 | Octapharma AG | Bikunin enthaltende plasmafraktion, verfahren zu ihrer herstellung und ihrer verwendung |
| AU2002224408B2 (en) | 2000-10-18 | 2007-08-23 | Massachusetts Institute Of Technology | Methods and products related to pulmonary delivery of polysaccharides |
| DE60120500T2 (de) | 2000-12-08 | 2007-06-06 | Genentech, Inc., South San Francisco | In Knorpelgeweben stark exprimiertes Gen |
| GB0114709D0 (en) | 2001-06-15 | 2001-08-08 | Pfizer Ltd | Stabilised formulations of amlodipine maleate |
| US20030027848A1 (en) | 2001-06-15 | 2003-02-06 | Anne Billotte | Stabilized formulations |
| US20040009212A1 (en) | 2002-01-30 | 2004-01-15 | Pharma Power Biotec Co. Ltd. | Mucoadhesive thermoresponsive medicament-carrier composition |
| DE10204462A1 (de) | 2002-02-05 | 2003-08-07 | Boehringer Ingelheim Pharma | Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse |
| AU2003226021B2 (en) | 2002-03-26 | 2008-07-17 | Teva Pharmaceutical Industries Ltd. | Drug microparticles |
| JP4180911B2 (ja) | 2002-12-27 | 2008-11-12 | 生化学工業株式会社 | 新規酵素活性測定方法 |
| WO2004082615A2 (en) | 2003-03-14 | 2004-09-30 | Nirmal Mulye | A process for preparing sustained release tablets |
| CN1160123C (zh) | 2003-05-26 | 2004-08-04 | 广东天普生化医药股份有限公司 | 乌司他丁用于治疗严重急性呼吸综合征的用途及其药物组合物 |
| WO2005030252A1 (en) | 2003-09-23 | 2005-04-07 | Pdl Biopharma, Inc. | Treatment of respiratory diseases with anti-il-2 receptor antibodies |
| EP3087991A1 (en) | 2003-11-08 | 2016-11-02 | Prothera Biologics | Composition of inter-alpha inhibitor proteins from human plasma for therapeutic use |
| EP3127916A1 (en) | 2004-06-07 | 2017-02-08 | Therapure Biopharma Inc. | Isolation of plasma or serum proteins |
| US7939282B2 (en) * | 2004-10-21 | 2011-05-10 | Rhode Island Hospital | Methods for detecting sepsis |
| CN101160133B (zh) | 2004-11-05 | 2013-01-09 | 普罗瑟拉生物公司 | 治疗用途的来自人血浆的内-α抑制剂蛋白质的制备和组合物 |
| CN103142650B (zh) | 2004-11-05 | 2016-05-11 | 普罗瑟拉生物公司 | 治疗用途的来自人血浆的内-α抑制剂蛋白质的制备和组合物 |
| US8182840B2 (en) | 2005-09-27 | 2012-05-22 | Tissue Tech, Inc. | Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition |
| BRPI0620316A2 (pt) | 2005-12-21 | 2011-11-08 | Wyeth Corp | formulações de proteìnas com viscosidades reduzida e seus usos |
| WO2008067655A1 (en) | 2006-12-05 | 2008-06-12 | Q6 Biomaterials Inc. | Biocompatible hydrogel-based scaffolds |
| US8026345B2 (en) | 2007-01-08 | 2011-09-27 | Hoffmann-La Roche Inc. | Characterization and identification of unique human adiponectin isoforms and antibodies |
| KR100846354B1 (ko) | 2007-03-21 | 2008-07-15 | (주) 프로탄바이오 | 혈청 당단백질부터 분리한 폐암 진단용 마커 |
| WO2009020481A2 (en) | 2007-05-08 | 2009-02-12 | Rq Bioscience, Inc. | Therapeutic compositions and methods for treating gram-negative bacterial infections |
| CN106928346B (zh) * | 2008-05-28 | 2021-09-07 | 普罗瑟拉生物公司 | 来自血液的间-α抑制物蛋白的制备和组合物 |
| HRP20160760T1 (hr) | 2008-07-18 | 2016-08-12 | A1M Pharma Ab | Medicinska uporaba čistača radikala i antioksidacijskog alfa-1-mikroglobulina |
| US20110236381A1 (en) | 2008-12-10 | 2011-09-29 | Stavros Garantziotis | Inhibition of inter-alpha trypsin inhibitor for the treatment of airway disease |
| WO2011150284A2 (en) | 2010-05-26 | 2011-12-01 | Baxter International Inc. | Removal of serine proteases by treatment with finely divided silicon dioxide |
| WO2011150944A1 (en) | 2010-06-04 | 2011-12-08 | Trifoilium Aps | Trefoil factors (tff) for the treatment of chronic pulmonary diseases |
| US9562906B2 (en) | 2010-06-10 | 2017-02-07 | National University Of Singapore | Methods for detection of gastric cancer |
| SG187599A1 (en) | 2010-07-23 | 2013-03-28 | Baxter Int | Manufacture of inter -alpha - inhibitor proteins (iaip) from plasma |
| WO2012119065A2 (en) | 2011-03-03 | 2012-09-07 | Seachaid Pharmaceuticals, Inc. | Antifungal agents and uses thereof |
| JP2013101047A (ja) | 2011-11-08 | 2013-05-23 | Nagasaki Univ | １４−３−３蛋白γアイソフォーム特異的ＥＬＩＳＡ |
| SI3677252T1 (sl) | 2012-03-19 | 2024-02-29 | Cidara Therapeutics, Inc. | Sheme odmerjanja za spojine iz razreda ehinokandinov |
| ES2846789T3 (es) | 2012-07-11 | 2021-07-29 | Tissuetech Inc | Composiciones que contienen complejos HC-HA/PTX3 y métodos de uso de los mismos |
| WO2014039987A2 (en) | 2012-09-09 | 2014-03-13 | Prothera Biologics, Inc. | Treatment of disease using inter-alpha inhibitor proteins |
| US20140206844A1 (en) | 2013-01-18 | 2014-07-24 | Prothera Biologics | Methods for isolating blood products from an inter-alpha inhibitor protein-depleted blood product material |
| WO2015071402A1 (en) | 2013-11-15 | 2015-05-21 | Nestec S.A. | Compositions for use in the prevention or treatment of necrotizing enterocolitis in infants and young children |
| JP6183174B2 (ja) | 2013-11-26 | 2017-08-23 | ユーハ味覚糖株式会社 | ヒアルロン酸高含有固形食品及びその製造方法 |
| WO2016138476A1 (en) | 2015-02-26 | 2016-09-01 | Mycotechnology, Inc. | Methods for lowering gluten content using fungal cultures |
| WO2018053029A1 (en) | 2016-09-13 | 2018-03-22 | Prothera Biologics, Inc. | Methods for treating pulmonary disease using inter-alpha inhibitor proteins |
| BR112019022358A2 (pt) | 2017-04-25 | 2020-05-19 | Prothera Biologics, Inc. | métodos para quantificar proteínas inibidoras inter-alfa |
| US20210393750A1 (en) | 2018-10-24 | 2021-12-23 | Prothera Biologics, Inc. | Inter-alpha inhibitor proteins and methods of use thereof |
| US20230416342A1 (en) | 2020-11-16 | 2023-12-28 | Prothera Biologics, Inc. | Methods for purifying inter-alpha inhibitor proteins |
-
2018
- 2018-04-25 BR BR112019022358-4A patent/BR112019022358A2/pt unknown
- 2018-04-25 US US16/608,531 patent/US20200057077A1/en not_active Abandoned
- 2018-04-25 CN CN201880027257.2A patent/CN110691973B/zh active Active
- 2018-04-25 JP JP2019558662A patent/JP7293128B2/ja active Active
- 2018-04-25 WO PCT/US2018/029436 patent/WO2018200722A1/en not_active Ceased
- 2018-04-25 AU AU2018258466A patent/AU2018258466B2/en active Active
- 2018-04-25 KR KR1020197034223A patent/KR102587810B1/ko active Active
- 2018-04-25 EP EP18792200.0A patent/EP3615937B1/en active Active
- 2018-04-25 CA CA3061164A patent/CA3061164A1/en active Pending
-
2019
- 2019-10-22 IL IL270069A patent/IL270069B1/en unknown
-
2021
- 2021-08-17 US US17/404,841 patent/US12265090B2/en active Active
-
2023
- 2023-02-17 JP JP2023023295A patent/JP2023085249A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020517967A5 (https=) | ||
| JP7441662B2 (ja) | ｐＫａｌ関連疾病の評価、アッセイおよび治療 | |
| CN104160039B (zh) | 川崎病的生物标志物 | |
| JP7293128B2 (ja) | インターα阻害剤タンパク質を定量化する方法 | |
| JP2013503643A (ja) | 関節リウマチの治療、診断及びモニターするための方法 | |
| CN103543271A (zh) | 诊断方法 | |
| JP2012513591A (ja) | 敗血症の検出のための方法 | |
| EP3546943A1 (en) | Composition for diagnosis of diseases | |
| JP2018517775A (ja) | クローン病を治療する方法 | |
| US9506923B2 (en) | Method of diagnosing surgical site infections | |
| JP2020521973A (ja) | 腎機能を診断またはモニターする方法、または腎機能障害を診断する方法 | |
| WO2019110706A1 (en) | Methods for predicting the risk of developing a sepsis or a systemic inflammatory response syndrome (sirs) | |
| CN101133323B (zh) | 溃疡性大肠炎或间质性肺炎的病期判定方法及其病期判定用试剂盒 | |
| Rotar et al. | Utility of Presepsin for diagnosis of infected acute necrotizing pancreatitis | |
| US20230055086A1 (en) | Inter-alpha inhibitor proteins | |
| Rottier et al. | Systemic neutrophil activation products as biomarker in patients with acute abdominal pain, a hypothesis forming study | |
| WO2025058047A1 (ja) | 補体関連疾患を検査する方法 | |
| JP2025522757A (ja) | ラナデルマブ治療のためのタンパク質バイオマーカー | |
| WO2024085195A1 (ja) | 免疫関連有害事象腸炎の検査方法 | |
| Liu et al. | T1631 The Validity of Ki-67 as a Prognostic Indicator in Patients With Appendiceal Carcinoid Tumor | |
| Iqbal et al. | T1633 Perioperative Management of Oral Anticoagulation for Elective Colon and Rectal Abdominal Procedures | |
| Popova | A STUDY OF SERUM LEVELS OF RANKL AND OPG INPATIENTS WITH ACUTE CORONARY SYNDROME WITH AND WITHOUT PSORIATIC ARTHRITIS | |
| EA045401B1 (ru) | Способы количественного определения интер-альфа ингибиторных белков | |
| JP2012075341A (ja) | 消化管間質腫瘍の検出用マーカー |